Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 18/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.60 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.60 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.60 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.60 |
| ▸ | CLK1 | P49759 | 1/20 | 0.60 |
| ▸ | CLK2 | P49760 | 1/20 | 0.60 |
| ▸ | PRKDC | P78527 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787942 | 1.00 | PIK3CG (0.60) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1787048 | 0.93 | PIK3CG (0.62) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1786677 | 0.90 | PIK3CG (0.70) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1789221 | 0.90 | PIK3CG (0.65) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1784566 | 0.89 | PIK3CG (0.60) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1785414 | 0.88 | PIK3CG (0.61) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL2260708 | 0.88 | PIK3CG (0.63) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1787858 | 0.88 | PIK3CG (0.65) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1783963 | 0.87 | PIK3CG (0.64) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1784707 | 0.87 | PIK3CG (0.63) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | claimed |
| US-20110124624-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| US-20110124693-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124693-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | PIK3CA, JAK2, JAK1 | PIK3CG 6/4885PIK3CA 1/4885PIK3CD 12/4885 |
| US-20110124624-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | PIK3CA, JAK2, JAK3 | PIK3CG 6/4885PIK3CA 1/4885PIK3CD 10/4885 |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | PI4KA, IP6K3, PHOSPHO1 | PIK3CG 23/4885PIK3CA 16/4885PIK3CD 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.